Table 2.
The summary of candidate vaccines in clinical phase.
| Approach | Platform* | The number of candidate vaccines (5) | The percent of candidate vaccines in total |
|---|---|---|---|
| Whole-microbe approach | IV | 21 | 15% |
| LAV | 2 | 1% | |
| VVr | 4 | 3% | |
| VVnr | 21 | 15% | |
| VVr + APC | 2 | 1% | |
| VVnr + APC | 1 | 1% | |
| BacAg-SpV | 1 | 1% | |
| Subunit approach | VLP | 6 | 4% |
| PS | 48 | 33% | |
| Genetic approach | DNA | 16 | 11% |
| RNA | 24 | 17% |
*IV, inactivated virus; LAV, live-attenuated virus; VVr, viral vector replicating; VVnr, viral vector non-replicating; VVr + APC, VVr + antigen-presenting cell; VVnr + APC, VVnr + antigen-presenting cell; BacAg-SpV, bacterial antigen-spore expression vector; VLP, virus-like particle; PS, protein subunit.